The 46 references in paper Andrey Pavlysh Vladislavovich, Aleksei Kolbin Sergeevich, Roman Gapeshin Andreevich, Stanislav Malyshev Mikhailovich, Андрей Павлыш Владиславович, Алексей Колбин Сергеевич, Роман Гапешин Андреевич, Станислав Малышев Михайлович (2015) “Причины сложности проведения фармакоэкономического анализа для орфанных лекарств. Пути решения // REASONS FOR DIFFICULTY OF THE PHARMACOECONOMIC ANALYSIS FOR ORPHAN DRUGS. WAYS FOR SOLUTIONS” / spz:neicon:pharmacoeconomics:y:2015:i:2:p:3-10

1
Ministry of Health data on the number of patients with orphan diseases to re-registers, the number of prescriptions written, in terms of funding. [Dannye Minzdrava po kolichestvu bol'nykh orfannymi zabolevaniyami v registre, po kolichestvu vypisannykh retseptov, po ob'emu finansirovaniya (In Russian)]. URL:https://www.rosminzdrav. ru/opendata (accessed 12.03.2015)
(check this in PDF content)
2
Health Technology Assessment: Manual, ed. Ed. YB Belousov. [Otsenka meditsinskikh tekhnologii: metod. posob. Pod obshch. red. Yu.B. Belousova (In Russian)]. Moscow. 2013; 42.
(check this in PDF content)
3
Government Decree of 26.04.2012 N 403 (ed. By 04.09.2012) «On the order of the Federal Register of persons suffering from lifethreatening and chronic progressive rare (orphan) diseases that can shorten life expectancy of citizens or their disability, and regional segment. [Postanovlenie Pravitel'stva RF ot 26.04.2012 N 403 (red. ot 04.09.2012) «O poryadke vedeniya Federal'nogo registra lits, stradayushchikh zhizneugrozhayushchimi i khronicheskimi progressiruyushchimi redkimi (orfannymi) zabolevaniyami, privodyashchimi k sokrashcheniyu prodolzhitel'nosti zhizni grazhdan ili ikh invalidnosti, i ego regional'nogo segmenta» (In Russian)]. URL: http:// base.consultant.ru/cons/cgi/online.cgi?
(check this in PDF content)
4
Federal Law of 21.11.2011 N 323-FZ (ed. By 06.04.2015) «On the basis of the health of citizens in the Russian Federation» (rev. And ext., Joined. In force from 05.09.2015). [Federal'nyj zakon ot 21.11.2011 N 323FZ (red. ot 06.04.2015) «Ob osnovah ohrany zdorov'ja grazhdan v Rossijskoj Federacii» (s izm. i dop., vstup. v silu s 09.05.2015) (In Russian)]. URL: http://base.consultant.ru/cons/cgi/online.cgi?req=doc;base=LAW; n=176374;div=LAW;dst=100465,0;rnd=0.0031823667231947184 (accessed 12.03.2015).
(check this in PDF content)
5
Aballea S., Toumi M., Vataire A., et al. Quantitative Analysis of the Influence of Disease and Product Characteristics on Orphan Drug Prices in Europe. Value In Health. 2010; 13 (3): A82.
(check this in PDF content)
6
Batshaw M., Groft S., Krischer J. Research Into Rare Diseases of Childhood. JAMA. 2014; 311 (17): 1729-1730.
(check this in PDF content)
7
Cohen D., Reynolds M. Interpreting the Results of CostEffectiveness Studies. J Am Coll Cardiol. 2008; 52: 2119-2126.
(check this in PDF content)
8
Commission of the European Communities (2000). Commission Regulation (EC) No 847/2000 of 27 April 2000 laying down the provisions for implementation of the criteria for designation of a medicinal product as an orphan medicinal product and definitions of the concepts «similar medicinal product» and «clinical superiority». Official Journal of the European Communities. 2000; 28 (4).
(check this in PDF content)
9
Congress Public Law 280, 107th. From the U.S. Government Printing Office. Page 1987. RARE DISEASES ACT OF 2002. URL: http:// www.gpo.gov/fdsys/pkg/PLAW-107publ280/html/PLAW-107publ280. htm (accessed: 12.03.2015)
(check this in PDF content)
10
Coyle D., Cheung M., Evans G. Opportunity Cost of Funding Drugs for Rare Diseases: The Cost-Effectiveness of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria. Med Decis Making. 2014; 34: 1016-1029.
(check this in PDF content)
11
Denis A., Mergaert L., Fostier C., et al. A comparative study of European rare disease and orphan drug markets. Health Policy. 2010; 97: 173-179.
(check this in PDF content)
12
Douglas C., Wilcox E., Burgess M., et al. Why orphan drug coverage reimbursement decision-makingneeds patient and public involvement. Health Policy. 2015; 119: 588-596.
(check this in PDF content)
13
Drummond M., Towse A. Orphan drugs policies: a suitable case for treatment. Eur J Health Econ. 2014; 15: 335-340.
(check this in PDF content)
14
Ferner R., Hughes D. The problem of orphan drugs. BMJ. 2010; 341: c6456.
(check this in PDF content)
15
Finkel M. The Orphan Drug Act and the Federal Government's Orphan Products Development Program. Public Health Reports. 1984; 99 (3): 313-316.
(check this in PDF content)
16
Fox J. Rare-disease drugs boosted by new Prescription Drug User Fee Act. Nature Biotechnology. 2012; 30 (8): 733-734.
(check this in PDF content)
17
Hall A., Carlson M. The current status of orphan drug development in Europe and the US. Intractable & rare diseases research. 2014; 3 (1): 1-7.
(check this in PDF content)
18
Hollis A. In: Health services restructuring in Canada: new evidence and new directions. Beach C, editor. Montreal: McGillQueen's University Press; 2006. Drugs for rare diseases: paying for innovation.
(check this in PDF content)
19
Hughes D., Tunnage B., Yeo S. Drugs for exceptionally rare diseases: do they deserve special status for funding? Q J Med. 2005; 98: 829-836.
(check this in PDF content)
20
Hyry H., Stern A., Cox T., et al. Limits on use of health economic assessments for rare diseases. Q J Med. 2014; 107: 241-245.
(check this in PDF content)
21
Jakubiak-Lasocka J., Jakubczyk M. Cost-effectiveness versus Cost-Utility Analyses: What Are the Motives Behind Using Each and How Do Their Results Differ? – A Polish Example. Value In Health Regional. 2014; 4C: 66-74.
(check this in PDF content)
22
Jessop N. The Dilemma with Orphan Drugs. Pharmaceutical Technology Europe. 2013; 25 (8): 8-9.
(check this in PDF content)
23
Joppi R., Bertele V., Garattini S. Orphan drugs, orphan diseases. The first decade of orphan drug legislation in the EU. Eur J Clin Pharmacol. 2013; 69: 1009-1024.
(check this in PDF content)
24
Kanters T., Steenhoek A., Hakkaart L. Budget Impact of Orphan Drugs In the Netherlands In The Period 2006-2012. Value In Health. 2014; 17 (7): A525.
(check this in PDF content)
25
Kesselheim A., Gagne J. Strategies for Postmarketing Surveillance of Drugs for Rare Diseases. Clinical pharmacology & Therapeutics. 2014; 95 (3): 265-268.
(check this in PDF content)
26
Logviss K., Krievins D., Purvina S. Rare diseases and orphan drugs: Latvian story. Orphanet Journal of Rare Diseases. 2014; 9 (1): 147.
(check this in PDF content)
27
Loughnot D. Potential interactions of the Orphan Drug Act and pharmacogenomics: A flood of orphan drugs and abuses? Am J Law Med. 2005; 31 (2-3): 365-380.
(check this in PDF content)
28
Luzatto L., Hollak C., Cox T., et al. Rare diseases and effective treatments: are we delivering? Lancet. 2015; 385 (9970): 750-752.
(check this in PDF content)
29
Messori A., Cicchetti A., Patregani L. Orphan drugs. Relating price determination to disease prevalence. BMJ. 2010; 341: c4615.
(check this in PDF content)
30
Michel M., Toumi M. Access to orphan drugs in Europe: current and future issues. Expert Rev. Pharmacoeconomics Outcomes Res. 2012; 12 (1): 23-29.
(check this in PDF content)
31
Miners A. Estimating 'Costs' for Cost-Effectiveness Analysis. PharmacoEconomics. 2008; 26 (9): 745-751.
(check this in PDF content)
32
Murphy S., Puwanant A., Griggs R., et al. Unintended Effects of Orphan Product Designation for Rare Neurological Diseases. Ann Neurol. 2012; 72: 481-490.
(check this in PDF content)
33
Picavet E., Cassiman D., Simoens S. What is known about the cost-effectiveness of orphan drugs? Evidence from cost-utility analyses. Journal of Clinical Pharmacy and Therapeutics. 2015; 40: 304-307.
(check this in PDF content)
34
Picavet E., Dooms M., Cassiman D. et al. Orphan Drugs for Rare Diseases: Grounds for Special Status. Drug Development Research. 2012; 73:115-119.
(check this in PDF content)
35
Picavet E., Dooms M., Cassiman D., et al. Drugs for rare diseases: Influence of orphan designation status on price. Appl Health Econ Health Policy. 2011; 9 (4): 275-279.
(check this in PDF content)
36
Picavet E., Morel T., Cassiman D., et al. Shining a light in the black box of orphan drug pricing. Orphanet J Rare Dis. 2014; 9 (1): 62.
(check this in PDF content)
37
Rare Disease Act of 2002. http://history.nih.gov/research/ downloads/PL107-280.pdf (accessed 12.03.2015).
(check this in PDF content)
38
Roos J., Hyry H., Cox T. Orphan drug pricing may warrant a competition law investigation. BMJ. 2010; 341 (7782): 1084-1086.
(check this in PDF content)
39
Schunemann H., Hill S., Guyatt G., et al. The GRADE approach and Bradford Hill’s criteria for causation. J Epidemiol Community Health. 2011; 65: 392-395.
(check this in PDF content)
40
Simoens S. Pricing and reimbursement of orphan drugs: the need for more transparency. Orphanet J Rare Dis. 2011; 6 (1): 42.
(check this in PDF content)
41
Simoens S., Cassiman D., Dooms M., et al. Orphan Drugs for Rare Diseases. Is it Time to Revisit Their Special Market Access Status? Drugs. 2012; 72 (11): 1437-1443.
(check this in PDF content)
42
Simoens S., Cassiman D., Picavet E., et al. Are some orphan drugs for rare diseases too expensive? A study of purchase versus compounding costs. Drugs Ther Perspect. 2011; 27 (10): 24-26.
(check this in PDF content)
43
Simoens S., Picavet E., Dooms M., et al. Cost-Effectiveness Assessment of Orphan Drugs. Appl Health Econ Health Policy. 2013; 11: 1-3.
(check this in PDF content)
44
US Code of Federal Regulations (CFR) Title 21 Food and Drugs Part 316.31 Scope of 44. Orphan Drug Exclusive Approval. URL http:// www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch. cfm?fr=316.31. (accessed: 12.03.2015)
(check this in PDF content)
45
Vegter S., Rozenbaum M., Postema R., et al. Review of Regulatory Recommendations for Orphan Drug Submissions in the Netherlands and Scotland: Focus on the Underlying Pharmacoeconomic Evaluations. Clinical Therapeutics. 2010; 32 (9): 1651-1661.
(check this in PDF content)
46
Winquist E., Bell C., Clarke J., et al. An Evaluation Framework for Funding Drugs for Rare Diseases. Value In Health. 2012; 15: 982-986. Сведения об авторах: Павлыш Андрей Владиславович – к.м.н., докторант кафедры общественного здоровья и здравоохранения, Первый Санкт-Петербургский государственный медицинский университет им. академика И.П. Павлова. Адрес: ул. Льва Толстого, д. 6-8, Санкт-Петербург, Россия, 197022; начальник службы
(check this in PDF content)